External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

Dr. Reddy's Laboratories / Equity Bottom-Up

<ul><li>Reported revenue grew by 16.5% YoY, driven by strong growth in the North America business (18% YoY) and India business (18% YoY).</li><li>The Europe business grew by 9% YoY, while emerging markets and the API business each grew by 20% YoY.</li><li>Gross margins stood at 70.6%, remaining mostly flat YoY due to the same product mix. However, reported EBITDA margins were 26.5%.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Reported revenue grew by 16.5% YoY, driven by strong growth in the North America business (18% YoY) and India business (18% YoY).The Europe business grew by 9% YoY, while emerging markets and the API business each grew by 20% YoY.Gross margins stood at 70.6%, remaining mostly flat YoY due to the same product mix. However, reported EBITDA margins were 26.5%.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr. Reddy’s Laboratories Ltd - Potential Investments & Pipelines to Unlock Value